



Prophylaxis for Hereditary Angioedema with Lanadelumab and C1 Inhibitors: Effectiveness and Value

Thursday • October 25, 2018 • 10:00 am to 3:00 pm

California Endowment Oakland Conference Center, 2000 Franklin Street, Oakland, CA 94612

Time	Activity
9:30 am – 10:00 am	Registration
10:00 am – 10:15 am	Meeting Convened and Opening Remarks Steve Pearson, MD, MSc, President, ICER
10:15 am – 11:15 am	Presentation of the Evidence and Economic Modeling Grace A. Lin, MD, MAS, University of California, San Francisco Solomon Lubinga, PhD, MSc, University of Washington <i>*Followed by Q & A/Discussion</i>
11:15 am – 11:25 am	Public Comments and Discussion
11:25 am – 11:35 am	Manufacturer Public Comments and Discussion
11:35 am – 12:20 pm	Lunch
12:20 pm – 1:20 pm	CTAF Vote on Clinical Effectiveness and Value
1:20 pm – 1:35 pm	Break
1:35 pm – 2:35 pm	Policy Roundtable
2:35 pm – 3:00 pm	Reflections from CTAF
3:00 pm	Meeting Adjourned

Institute for Clinical and Economic Review (ICER) Staff and Consultants	
Foluso Agboola, MBBS, MPH,* Director, Evidence Synthesis, ICER	Steve Pearson MD, MSc,* President, ICER
Laura Cianciolo, BA,* Program Associate, ICER	David Rind, MD, MSc,* Chief Medical Officer, ICER
Grace A. Lin, MD, MAS,* Associate Professor, University of California, San Francisco	Matthew Seidner, BS,* Program Director, ICER
Solomon Lubinga, PhD, MSc,* Senior Fellow, University of Washington	David Whitrap, BA, BES,* Vice President of Communications and Outreach

*No conflicts of interest to disclose, defined as individual health care stock ownership in any health plan or pharmaceutical, biotechnology, or medical device manufacturers, or any health care consultant income or honoraria from health plans or manufacturers.



Participating Members of CTAF

Felicia Cohn, PhD,* Bioethics Director, Kaiser Permanente, Orange County	Joy Melnikow, MD, MPH,* Director, Center for Healthcare Policy and Research, University of California, Davis
Robert Collyar,* Patient Advocate	Elizabeth J. Murphy, MD, DPhil,* Professor of Clinical Medicine, University of California San Francisco; Chief, Division of Endocrinology and Metabolism, Zuckerberg San Francisco General Hospital
Rena K. Fox, MD,* Professor of Medicine, University of California, San Francisco	Patricia E. Powers, MPA,* Executive Director, Center for Healthcare Decisions
Kimberly Gregory, MD, MPH,* Vice Chair, Women’s Healthcare Quality and Performance Improvement, Cedars-Sinai Medical Center	Rita F. Redberg, MD, MSc, FACC,* Professor, University of California, San Francisco School of Medicine
Paul Heidenreich, MD, MS (Chair),* Professor and Vice-Chair for Quality, Clinical Affairs, and Analytics, Stanford University	William Remak, BSc, MT, BPH,* Chairman/CEO, California Hepatitis C Task Force, Inc
Jeffrey Hoch, PhD,* Associate Director, Center for Healthcare Policy and Research, University of California, Davis	Robert Rentschler, MD,* Retired, Beaver Medical Group
Jeffrey Klingman, MD,* Chief of Neurology, The Permanente Medical Group	Alexander Smith, MD, MPH,* Associate Professor of Medicine, University of California, San Francisco
Annette Langer-Gould, MD, PhD,* Regional Lead for Clinical and Translational Neuroscience, Southern California Permanente Medical Group, Kaiser Permanente	

* No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member’s household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

Policy Roundtable Participant	Conflict of Interest
Debra Bensen-Kennedy, MD, Vice President, Medical Affairs, CSL Behring	Full-time employee of CSL Behring.
Marco Cicardi, MD, Professor of Medicine, Università degli Studi di Milano, Italy	Received consultancy fees from Shire and CSL Behring; speaker for Shire, CSL Behring, and Pharming; received research and educational support from Shire and Pharming; principal investigator in lanadelumab, Ruconest, and Haegarda clinical trials.
April Kunze, PharmD, Senior Director, Formulary Development and Trend Management Strategy, Prime Therapeutics	Full-time employee of Prime Therapeutics.
Stephanie Smith, Patient Advocate	Receives honoraria for work as a patient advocate for Haegarda and CSL Behring.